Bio-Rad Laboratories, Inc. Class A Common Stock vs Braze Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Braze Inc trades at $28.06 (market cap $3.18B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3× Braze Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| BIO | BRZE | |
|---|---|---|
Market Cap | $9.43B | $3.18B |
Sector | Health | Technology |
52-Week High | $356.25 | $36.19 |
52-Week Low | $241.71 | $15.79 |
Enterprise Value | $9.18B | $2.87B |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →